Technical Analysis for ZOM - Zomedica Pharmaceuticals Corp

Grade Last Price % Change Price Change
grade F 0.3427 -6.75% -0.0248
ZOM closed down 6.75 percent on Friday, November 29, 2019, on 61 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down
See historical ZOM trend table...

Date Alert Name Type % Chg
Hot IPO Pullback Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
New 52 Week Low Weakness 0.00%
Gapped Down Weakness 0.00%
Narrow Range Bar Range Contraction -6.75%
Gapped Down Weakness -6.75%
Pocket Pivot Bullish Swing Setup -21.09%
Narrow Range Bar Range Contraction -21.09%
Gapped Up Strength -21.09%
Older signals for ZOM ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs. It is also developing ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. The company has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system, as well as a development agreement with IncellDx, Inc. Zomedica Pharmaceuticals Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Health RTT Cancer Pharmaceuticals Drugs Chemical Substances Hyperthyroidism

Is ZOM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 2.25
52 Week Low 0.3302
Average Volume 54,489
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 0.0000
10-Day Moving Average 0.9735
Average True Range 0.2351
ADX 0.0
+DI 10.4801
-DI 59.4136
Chandelier Exit (Long, 3 ATRs ) 1.5447
Chandelier Exit (Short, 3 ATRs ) 1.0355
Upper Bollinger Band 0.0000
Lower Bollinger Band 0.0000
Percent B (%b) 0.0
BandWidth 0.0000
MACD Line -0.3471
MACD Signal Line -0.1637
MACD Histogram -0.1833
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.3726
Resistance 3 (R3) 0.3717 0.3609 0.3676
Resistance 2 (R2) 0.3609 0.3533 0.3613 0.3659
Resistance 1 (R1) 0.3518 0.3486 0.3464 0.3527 0.3643
Pivot Point 0.3410 0.3410 0.3383 0.3414 0.3410
Support 1 (S1) 0.3319 0.3334 0.3265 0.3328 0.3211
Support 2 (S2) 0.3211 0.3287 0.3215 0.3195
Support 3 (S3) 0.3120 0.3211 0.3178
Support 4 (S4) 0.3129